Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Sources: SURMOUNT-5 Clinical Trial (May 2025, The first head-to-head trial comparing the efficacy and safety of tirzepatide versus semaglutide for obesity management, detailing differences in total weight reduction
Given the uncertainty of this outcome, additional clinical studies of obese AUD patients should explore the effects of the GLP-1R agonists on alcohol intake and body weight
When researchers place an order they will receive products packaged to research standards with proper labeling and documentation
Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption
Most studies have a low risk of bias in selective outcome data ( Figures 2 , 3 )
US$ 26.71
US$ 29.28
US$ 27.74
